The Charade of New Drug Approvals for Schizophrenia
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
Relapse in Antipsychotic Drug Trials is Poorly Defined
There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
The Rise of the Digital Asylum
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.
How Do We Test the Effects of Long-Term Exposure to Antipsychotics?
A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.
How Exercise Can Help With First Episode Psychosis
New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.
Review Finds FDA Approval of Digital Antipsychotic Misguided
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
Lack of Clear Guidelines Prevent Clinicians from Reducing Antipsychotics
A recently published study from noted critical psychiatry expert Joanna Moncrieff explored the barriers that prevent clinicians from helping service users in discontinuing or...
Discontinuation of Antipsychotics Improves Cognitive Functioning
A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...
Anticholinergic Psychiatric Drugs Linked to a 50% Increase in Dementia
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.
Service-Users See Long-Term Antipsychotic Use as Compromising Recovery, Review Finds
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Better Outcomes Off Medication for Those Recovered from First-Episode Schizophrenia
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
Antipsychotics Associated with High Risk of Death in Children
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Claims That Long-term Antipsychotic Use Leads to Better Outcomes are Misleading, Researchers Argue
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
Researchers Warn of “Brain Atrophy” in Children Prescribed Antipsychotics
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Two-Thirds of Schizophrenia Patients Do Not Remit on Antipsychotics
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
New Review of Antipsychotics for Schizophrenia Questions Evidence for Long Term Use
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Call to Monitor Adverse Effects of Antipsychotics in Youth
Researchers point to the risks of using antipsychotics with youth and caution against the practice.
Study Reduces Over-prescription of Antipsychotics in Older Adults
New intervention shows promise in reducing over-prescription of off-label antipsychotics in older adults.
New Research Suggests Brain Abnormalities in ‘Schizophrenia’ May Result From Antipsychotics
Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.
FDA Defends Decision to Approve Digital Aripiprazole
Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.
Effort to Tackle Overuse of Antipsychotics in Older Adults Backfires
A partnership designed to decrease antipsychotic use in elderly patients may have led to increased use of medications with even worse risk/benefit profiles.
A Tale of Two Studies
With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?
Researchers Challenge Industry-Friendly Depression Guideline
Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.
Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia
A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.
Reducing Antipsychotic Use May Improve Health for People with Mental Health Diagnoses
A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..
